Drug Profile


Alternative Names: Famciclovir/celecoxib; IMC-1

Latest Information Update: 02 Feb 2016

Price : $50

At a glance

  • Originator Innovative Med Concepts
  • Class Antirheumatics; Antivirals; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Nucleosides; Purines; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Fibromyalgia

Highest Development Phases

  • Phase II Fibromyalgia

Most Recent Events

  • 07 Mar 2017 Innovative Med Concepts plans phase III trial for Fibromyalgia
  • 28 Jan 2016 Celecoxib/famciclovir receives Fast Track designation for Fibromyalgia [PO] in USA
  • 20 Nov 2014 Celecoxib/famciclovir is available for licensing as of 20 Nov 2014. www.innovativemedconcepts.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top